Feasibility, safety, and efficacy of stereotactic body radiotherapy combined with intradermal heat-killed mycobacterium obuense (IMM-101) vaccination for non-progressive locally advanced pancreatic cancer, after induction chemotherapy with (modified)FOLFIRINOX – The LAPC-2 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Feasibility, safety, and efficacy of stereotactic body radiotherapy combined with intradermal heat-killed mycobacterium obuense (IMM-101) vaccination for non-progressive locally advanced pancreatic cancer, after induction chemotherapy with (modified)FOLFIRINOX – The LAPC-2 trial

Published:2023-06 Issue: Volume:183 Page:109541
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

van 't Land Freek R.,Latifi Diba,Moskie Miranda,Homs Marjolein Y.V.,Bosscha Koop,Bonsing Bert A.,Mieog Sven D.,van der Harst Erwin,Coene Peter-Paul L.O.,Wijsman Jan H.,van der Schelling George P.,Groot Koerkamp Bas,Nuyttens Joost J.,van Eijck Casper H.J.

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology

Reference39 articles.

1. Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma;Latenstein;Eur J Cancer,2020

2. Pancreatic cancer;Mizrahi;Lancet,2020

3. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis;Suker;Lancet Oncol,2016

4. FOLFIRINOX in locally advanced and metastatic pancreatic cancer: a single centre cohort study;Rombouts;J Cancer,2016

5. Systematic review of resection rates and clinical outcomes after FOLFIRINOX-based treatment in patients with locally advanced pancreatic cancer;Rombouts;Ann Surg Oncol,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP